Background and Objective: Aging is an inducement of sarcopenia to cause hypokinesia. Ursolic acid (UA) has various biologic activities in aging and muscle injury. The mechanism and correlation between UA and sarcopenia is unclear. Hence, the purpose of current study was to appraise the protection of UA on aged-relevant sarcopenia. Materials and Methods: The aging mouse model was established by D-galactose. Muscle force was tested according to the grip strength meter. The levels of oxidation indices were measured by spectrophotometer. The levels of inflammatory indexes were analyzed by ELISA kits. The expressions of FBXO-32, MURF-1, Collagen-I, TGF-β, BAX and BCL-2 were detected by western blot. Results: The UA enhanced muscle mass and grip strength to mitigate D-galactose-induced muscle dysfunction. In serum, UA restrained oxidative stress and inflammatory response to improve internal environment homeostasis and delay body decrepitude. In skeletal muscle, UA reduced FBXO-32, MURF-1, Collegan-I and TGF-β1 expressions to mitigate D-gal-induced muscle dystrophy and fibrosis. In molecular mechanism, UA decreased BAX and increased BCL-2 expressions to inhibit apoptosis. Concision: The UA was considered a functional agent due to its amelioration on apoptosis.